Baidu
map

JAMA Neurology:胰岛素抗性会增加患阿尔兹海默病风险

2015-07-29 佚名 生物谷

众所周知,肥胖会增加患心血管疾病和某些癌症的风险。但爱荷华州立大学的一项新研究表明,记忆丧失应该是人们首要关心的问题。这项研究发表在《美国医学会神经病学》杂志上,该研究发现胰岛素抗性和记忆功能下降之间存在密切关联,这样就增加了患阿尔茨海默氏症的风险。科学家Auriel Willette说在肥胖患者、前驱糖尿病患者或2型糖尿病患者人群中胰岛素抗性是较常见的。Willette和Barbara Bend

众所周知,肥胖会增加患心血管疾病和某些癌症的风险。但爱荷华州立大学的一项新研究表明,记忆丧失应该是人们首要关心的问题。

这项研究发表在《美国医学会神经病学》杂志上,该研究发现胰岛素抗性和记忆功能下降之间存在密切关联,这样就增加了患阿尔茨海默氏症的风险。科学家Auriel Willette说在肥胖患者、前驱糖尿病患者或2型糖尿病患者人群中胰岛素抗性是较常见的。

Willette和Barbara Bendlin通过脑部扫描检查了150个处于阿尔茨海默氏症风险中的中老年人,但是还没有迹象显示他们记忆丧失。扫描发现如果人们有较高含量的胰岛素抗性水平时大脑区域使用的少量血糖最容易影响到阿尔茨海默氏症。当这种情况发生时,大脑会用很少的能量去传递信息和功能,Willette说。

“如果你没有足够的能量,你不会善于记住某事或做某事,”他说,“这对阿尔茨海默病是很重要的,因为在大脑某些区域中血糖的使用逐步减少。这些区域中血糖使用量最终会越来越少。”

Willette的工作主要集中于大脑内侧颞叶,特别是海马区,它是大脑学习新事物和长期记忆的一个关键区域。这也是由于阿尔茨海默氏症大脑首次显示大规模萎缩或收缩的区域,Willette说。

认知能力下降有直接影响

这是首次研究观察中老年人(平均年龄为60岁)胰岛素抗性情况,研究确定降低血糖使用的模式与阿尔茨海默氏症和记忆衰退的关系,Willette说。

胰岛素抗性和阿尔茨海默病之间的关联对预防来说是非常重要的,但风险也非常高。Willette说。血糖调节障碍的问题可能会在任何年龄段出现并影响认知功能。研究人员在肥胖患者中测试胰岛素抗性,建议采取改善营养和适度的运动等方式改善病情。这是至关重要的第一步,他说。

“基于将来可能会发生什么再来调整我们的行为是非常糟糕的。”Willette说。“这就是为什么人们需要知道胰岛素抗性或相关问题,这对治疗来说很重要。阿尔茨海默氏症不仅仅是在2型糖尿病的患者身上存在。甚至没有患2型糖尿病的病人也有轻度或中度胰岛素抗性,这些患者患有阿尔茨海默氏症的风险可能会增加,因为他们表现出许多相同类型的大脑区域和记忆的关系。”

理解认知能力下降的过程需要我们更进一步的研究。Willette说那些经历过痴呆和阿尔茨海默氏症不同阶段的高危人群将提供在他们的认知功能下降时观察周围所发生的事。

原始出处:

Auriel A. Willette, PhD1,2; Barbara B. Bendlin, PhD et al.Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle–Aged Adults at Risk for Alzheimer Disease.JAMA Neurology.July 27, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999540, encodeId=81e6199954081, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 06 22:05:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665910, encodeId=609c166591073, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Nov 12 23:05:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749561, encodeId=51d61e495610e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Apr 10 11:05:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816481, encodeId=f794181648139, content=<a href='/topic/show?id=ad819e769de' target=_blank style='color:#2F92EE;'>#阿尔兹海默病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97769, encryptionId=ad819e769de, topicName=阿尔兹海默病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Thu Apr 21 22:05:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402661, encodeId=915c140266165, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Fri Jul 31 05:05:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33832, encodeId=3b5b33832fd, content=:-(, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2d7opGcVf4ByPPZsDzyr5MfMPWbzbtAo4HDmK9tdAacSCxEPziakJia4uI3iaRfktfw6g9eOcwLfOV5/0, createdBy=efc41636350, createdName=1dd95637m50(暂无匿称), createdTime=Thu Jul 30 00:22:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33792, encodeId=f39833e923d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:50:00 CST 2015, time=2015-07-29, status=1, ipAttribution=)]
    2015-12-06 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999540, encodeId=81e6199954081, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 06 22:05:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665910, encodeId=609c166591073, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Nov 12 23:05:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749561, encodeId=51d61e495610e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Apr 10 11:05:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816481, encodeId=f794181648139, content=<a href='/topic/show?id=ad819e769de' target=_blank style='color:#2F92EE;'>#阿尔兹海默病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97769, encryptionId=ad819e769de, topicName=阿尔兹海默病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Thu Apr 21 22:05:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402661, encodeId=915c140266165, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Fri Jul 31 05:05:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33832, encodeId=3b5b33832fd, content=:-(, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2d7opGcVf4ByPPZsDzyr5MfMPWbzbtAo4HDmK9tdAacSCxEPziakJia4uI3iaRfktfw6g9eOcwLfOV5/0, createdBy=efc41636350, createdName=1dd95637m50(暂无匿称), createdTime=Thu Jul 30 00:22:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33792, encodeId=f39833e923d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:50:00 CST 2015, time=2015-07-29, status=1, ipAttribution=)]
    2015-11-12 yige2012
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999540, encodeId=81e6199954081, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 06 22:05:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665910, encodeId=609c166591073, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Nov 12 23:05:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749561, encodeId=51d61e495610e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Apr 10 11:05:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816481, encodeId=f794181648139, content=<a href='/topic/show?id=ad819e769de' target=_blank style='color:#2F92EE;'>#阿尔兹海默病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97769, encryptionId=ad819e769de, topicName=阿尔兹海默病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Thu Apr 21 22:05:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402661, encodeId=915c140266165, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Fri Jul 31 05:05:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33832, encodeId=3b5b33832fd, content=:-(, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2d7opGcVf4ByPPZsDzyr5MfMPWbzbtAo4HDmK9tdAacSCxEPziakJia4uI3iaRfktfw6g9eOcwLfOV5/0, createdBy=efc41636350, createdName=1dd95637m50(暂无匿称), createdTime=Thu Jul 30 00:22:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33792, encodeId=f39833e923d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:50:00 CST 2015, time=2015-07-29, status=1, ipAttribution=)]
    2016-04-10 baoya
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999540, encodeId=81e6199954081, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 06 22:05:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665910, encodeId=609c166591073, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Nov 12 23:05:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749561, encodeId=51d61e495610e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Apr 10 11:05:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816481, encodeId=f794181648139, content=<a href='/topic/show?id=ad819e769de' target=_blank style='color:#2F92EE;'>#阿尔兹海默病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97769, encryptionId=ad819e769de, topicName=阿尔兹海默病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Thu Apr 21 22:05:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402661, encodeId=915c140266165, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Fri Jul 31 05:05:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33832, encodeId=3b5b33832fd, content=:-(, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2d7opGcVf4ByPPZsDzyr5MfMPWbzbtAo4HDmK9tdAacSCxEPziakJia4uI3iaRfktfw6g9eOcwLfOV5/0, createdBy=efc41636350, createdName=1dd95637m50(暂无匿称), createdTime=Thu Jul 30 00:22:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33792, encodeId=f39833e923d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:50:00 CST 2015, time=2015-07-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999540, encodeId=81e6199954081, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 06 22:05:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665910, encodeId=609c166591073, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Nov 12 23:05:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749561, encodeId=51d61e495610e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Apr 10 11:05:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816481, encodeId=f794181648139, content=<a href='/topic/show?id=ad819e769de' target=_blank style='color:#2F92EE;'>#阿尔兹海默病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97769, encryptionId=ad819e769de, topicName=阿尔兹海默病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Thu Apr 21 22:05:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402661, encodeId=915c140266165, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Fri Jul 31 05:05:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33832, encodeId=3b5b33832fd, content=:-(, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2d7opGcVf4ByPPZsDzyr5MfMPWbzbtAo4HDmK9tdAacSCxEPziakJia4uI3iaRfktfw6g9eOcwLfOV5/0, createdBy=efc41636350, createdName=1dd95637m50(暂无匿称), createdTime=Thu Jul 30 00:22:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33792, encodeId=f39833e923d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:50:00 CST 2015, time=2015-07-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1999540, encodeId=81e6199954081, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 06 22:05:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665910, encodeId=609c166591073, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Nov 12 23:05:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749561, encodeId=51d61e495610e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Apr 10 11:05:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816481, encodeId=f794181648139, content=<a href='/topic/show?id=ad819e769de' target=_blank style='color:#2F92EE;'>#阿尔兹海默病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97769, encryptionId=ad819e769de, topicName=阿尔兹海默病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Thu Apr 21 22:05:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402661, encodeId=915c140266165, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Fri Jul 31 05:05:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33832, encodeId=3b5b33832fd, content=:-(, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2d7opGcVf4ByPPZsDzyr5MfMPWbzbtAo4HDmK9tdAacSCxEPziakJia4uI3iaRfktfw6g9eOcwLfOV5/0, createdBy=efc41636350, createdName=1dd95637m50(暂无匿称), createdTime=Thu Jul 30 00:22:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33792, encodeId=f39833e923d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:50:00 CST 2015, time=2015-07-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1999540, encodeId=81e6199954081, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Dec 06 22:05:00 CST 2015, time=2015-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665910, encodeId=609c166591073, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Nov 12 23:05:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749561, encodeId=51d61e495610e, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Sun Apr 10 11:05:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816481, encodeId=f794181648139, content=<a href='/topic/show?id=ad819e769de' target=_blank style='color:#2F92EE;'>#阿尔兹海默病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97769, encryptionId=ad819e769de, topicName=阿尔兹海默病风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Thu Apr 21 22:05:00 CST 2016, time=2016-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402661, encodeId=915c140266165, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Fri Jul 31 05:05:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33832, encodeId=3b5b33832fd, content=:-(, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2d7opGcVf4ByPPZsDzyr5MfMPWbzbtAo4HDmK9tdAacSCxEPziakJia4uI3iaRfktfw6g9eOcwLfOV5/0, createdBy=efc41636350, createdName=1dd95637m50(暂无匿称), createdTime=Thu Jul 30 00:22:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33792, encodeId=f39833e923d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:50:00 CST 2015, time=2015-07-29, status=1, ipAttribution=)]
    2015-07-29 快乐晴天

    0

相关资讯

FASEB :Omega-3脂肪酸和抗氧化剂补充剂或可对阿尔兹海默症有疗效

最新一项研究表明,鱼油补充剂和抗氧化剂对治疗阿尔茨海默氏症可能有效。2015年7月发表在《美国实验生物学学会联合会杂志》上的一篇新文章发现,患有轻度临床认知障碍的病人在认知障碍疾病的早期阶段可观察到β-淀粉样蛋白标志出现了间隙,并在神经组织中减少了炎症的发生。尽管在此项实验中研究了12个病人并且历时达4-17个月,但是调查结果显示这种相对经济且充足的补充剂在进一步临床研究中应该继续进行。 “研究

开玩笑!这个女博士三年发了45篇SCI!

博士三年可以完成哪些事情?有的小伙伴觉得发个三篇SCI已经非常不容易了!有的小伙伴觉得能完成毕业的指标就可以~今天,让我们来看看中国海洋大学的一位女博士的三年博士生涯,大伙儿都要加把劲啊! 你如法想象谭梦姗瘦小的身体里蕴藏着多大的力量,三年博士生活,谭梦姗发表了45篇SCI,其中第一作者和共同第一作者12篇,单篇最高影响因子10.11,第一作者累计影响因子52。课题“阿尔茨海默病发病的神

PLOS MED:抗高血压药物治疗或降低AD风险

 阿尔茨海默病(AD)流行趋势正处于上升的趋势,已经造成了越来越大的社会和经济压力。流行病学研究已经证明了潜在的可以修改的风险因子可以作为靶点来预防AD。这些风险因子包括了2型糖尿病和血糖特征、高血压、肥胖、吸烟、缺少体育锻炼、抑郁、血脂紊乱和较低的受教育程度。据报道,全球范围内有大约三分之一的AD病例是归因于这些风险因子的。考虑到实施大规模的风险因子修改的随机临床试验有着较大的难度,有

Plos Medicine:可控风险因素和阿尔兹海默症的关联

全球存在大约四千万老年痴呆症患者,而且数量还有增加的趋势,据估计到2050年全球将会有1.5亿老年痴呆患者。这些老年患者往往表现为记忆力下降,交流障碍和认知功能障碍。在这些老年痴呆患者中,最常见的是阿尔兹海默症(AD),大约占到60%-70%。研究者们一直在试图寻找AD的成因,尤其是那些可能的可控风险因素,因为通过控制这些因素可能可以降低AD的发病率。流行病学的研究已经发行了几种潜在的风险因素,例

2015年阿尔茨海默病协会国际会议

--- 药物疗法的临床试验数据结果带来新希望--- 早年生活的风险因素- 1型糖尿病和学校分数--- 对婴儿潮一代的影响-人数多、代价大--- 女性特殊的认知能力风险2015年阿尔茨海默病协会国际会议(Alzheimer's Association International Conference 2015,简称:AAIC 2015)报告了令人激动的新研究成果,涉及多个阿尔茨海默病及痴呆症的研

上海交通大学乐卫东团队阿尔茨海默病新发现

最新一期的神经病学权威杂志Alzheimer's & Dementia日前刊登了上海交通大学医学院附属瑞金医院神经病学研究所乐卫东教授课题组研究成果(Alzheimer's & Dementia. 2015 Jun 26. doi: 10.1016)。该杂志由国际阿尔茨海默病及痴呆协会主办,2014年该杂志的影响因子是12.407分。在乐教授的指导下,刘会博士等通过历时四年的时间,

Baidu
map
Baidu
map
Baidu
map